How to Read Your Hormone Lab Results: A Patient's Guide

At a glance
- TSH reference range / typically 0.4 to 4.0 mIU/L, but many endocrinologists target 0.5 to 2.5 mIU/L for symptom relief
- Free T4 normal range / 0.8 to 1.8 ng/dL in most labs
- Free T3 normal range / 2.3 to 4.2 pg/mL; often the last thyroid marker ordered but clinically important
- Total testosterone (males) / 264 to 916 ng/dL per most lab assays; the Endocrine Society defines deficiency at <300 ng/dL
- Estradiol (premenopausal females) / varies by cycle phase, from roughly 30 to 400 pg/mL
- Fasting insulin / typically 2.6 to 24.9 µIU/mL; values above 10 may signal early insulin resistance
- Cortisol (morning draw) / 6 to 18 µg/dL with peak levels between 7 and 9 AM
- DHEA-S / age- and sex-specific; declines roughly 2 to 3% per year after age 30
- Reference ranges vary by lab / always compare your result to the range printed on your own report
Why Reference Ranges Are Not the Same as Optimal Ranges
A reference range represents the middle 95% of values from a population of presumably healthy people who were tested at that laboratory. It is a statistical boundary, not a clinical target. Two people with the same TSH of 3.8 mIU/L may feel completely different depending on their age, symptoms, and free hormone levels.
How Labs Build Their Ranges
Most commercial laboratories derive reference intervals from the central 95th percentile of a sample population, following Clinical and Laboratory Standards Institute (CLSI) protocol 1. The problem: that population often includes individuals with undiagnosed subclinical thyroid disease, skewing the upper limit upward. The National Academy of Clinical Biochemistry (NACB) noted that if individuals with occult thyroid autoimmunity were excluded, the upper TSH reference limit would drop to approximately 2.5 mIU/L 2.
"Normal" vs. Symptomatic
A 2017 cross-sectional analysis of 9,981 euthyroid adults in the NHANES database found that fatigue prevalence increased progressively as TSH rose above 2.5 mIU/L, even though all values fell within the standard 0.4 to 4.0 range 3. Dr. Antonio Bianco, a professor of medicine at the University of Chicago and past president of the American Thyroid Association, has stated: "The reference range tells you where most people land. It does not tell you where a specific patient feels well" 4.
Your lab result is a data point. Context, symptoms, and trends over time determine whether that data point requires action.
The Thyroid Panel: TSH, Free T4, and Free T3
The thyroid panel is the most commonly ordered hormone test in the United States, with over 70 million TSH assays run annually. Reading it correctly requires understanding all three markers together, not TSH alone.
TSH (Thyroid-Stimulating Hormone)
TSH is a pituitary hormone. It rises when the thyroid gland underperforms and falls when the thyroid overproduces. Most labs list a reference range of 0.4 to 4.0 mIU/L, but the 2014 American Thyroid Association (ATA) guidelines acknowledge that the upper limit is debated and age-dependent 5. For adults under 65, many endocrinologists consider a TSH between 0.5 and 2.5 mIU/L preferable when symptoms are present.
A TSH above 10.0 mIU/L with a low free T4 confirms overt hypothyroidism. A TSH between 4.0 and 10.0 with a normal free T4 is classified as subclinical hypothyroidism, which the ATA recommends treating when TSH exceeds 10 mIU/L or when anti-TPO antibodies are elevated 5.
Free T4 (Thyroxine)
Free T4 measures the unbound, biologically available fraction of thyroxine. Normal range in most assays: 0.8 to 1.8 ng/dL. A free T4 in the lower third of the range alongside a TSH above 3.0 may explain persistent fatigue, cold intolerance, or weight gain even when both values are technically "within range."
Free T3 (Triiodothyronine)
Free T3 is the metabolically active thyroid hormone. Reference range: 2.3 to 4.2 pg/mL. Many standard panels omit it. A normal TSH with a low free T3 can indicate poor T4-to-T3 conversion, which occurs more frequently in patients with selenium deficiency, chronic stress, or caloric restriction 6.
The European Thyroid Association's 2012 guidelines noted that roughly 5 to 10% of levothyroxine-treated patients with a normal TSH still report residual symptoms, and low free T3 may explain the discrepancy 7.
Testosterone: Total, Free, and Bioavailable
Testosterone testing is relevant for both men and women. Misreading these results is common because labs report multiple fractions, each with different clinical significance.
Total Testosterone
Total testosterone includes both protein-bound and free hormone. The Endocrine Society's 2018 clinical practice guideline defines male hypogonadism as a total testosterone consistently below 300 ng/dL, confirmed on two morning samples drawn before 10 AM 8. This cutoff is based on population data from the Framingham Heart Study and the European Male Aging Study (EMAS).
Timing matters. Testosterone peaks between 7 and 9 AM and can drop 20 to 25% by mid-afternoon. A single afternoon draw may produce a falsely low reading.
Free Testosterone
Only 2 to 3% of circulating testosterone is unbound ("free"). The rest binds to sex hormone-binding globulin (SHBG) and albumin. A man with a total testosterone of 450 ng/dL but an SHBG of 65 nmol/L may have a free testosterone below the reference floor, explaining symptoms of low energy or decreased libido despite a "normal" total value.
Testosterone in Women
Women produce testosterone too, at roughly one-tenth the male concentration. A total testosterone above 45 to 50 ng/dL in a premenopausal woman may suggest polycystic ovary syndrome (PCOS), adrenal hyperplasia, or an ovarian source. Free testosterone is often more sensitive for detecting mild androgen excess. The 2023 international PCOS guideline recommends using liquid chromatography-tandem mass spectrometry (LC-MS/MS) assays rather than immunoassays for accurate female testosterone measurement 9.
Estradiol, Progesterone, and the Female Reproductive Panel
Interpreting female reproductive hormones requires knowing where the patient is in her menstrual cycle, her menopausal status, and whether she takes exogenous hormones.
Estradiol (E2)
Estradiol fluctuates dramatically across the menstrual cycle. Typical ranges by phase: early follicular 30 to 100 pg/mL, mid-cycle peak 100 to 400 pg/mL, luteal 50 to 200 pg/mL, postmenopausal <30 pg/mL. A single random estradiol without cycle-day context is difficult to interpret. For perimenopausal women experiencing hot flashes, a consistently low estradiol (below 30 pg/mL) alongside an elevated FSH (above 25 mIU/mL) supports the diagnosis of menopause 10.
Progesterone
A mid-luteal progesterone (drawn 7 days after ovulation, typically cycle day 21 in a 28-day cycle) above 3 ng/mL confirms ovulation. Values above 10 ng/mL suggest a stronger luteal phase. The American Society for Reproductive Medicine (ASRM) uses this threshold in fertility workups 11.
FSH and LH
Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) are pituitary markers. An FSH above 25 mIU/mL on cycle day 3 suggests diminished ovarian reserve. An LH-to-FSH ratio greater than 2:1 is a classic PCOS finding, although the 2023 PCOS guideline de-emphasized this ratio in favor of androgen levels and ultrasound criteria 9.
Cortisol and DHEA-S: The Adrenal Markers
Cortisol follows a circadian rhythm. A morning serum cortisol below 3 µg/dL is suspicious for adrenal insufficiency and warrants further testing with an ACTH stimulation test 12. A morning cortisol above 18 µg/dL is generally reassuring. Values between 3 and 18 µg/dL are indeterminate.
Why Random Cortisol Is Unreliable
A cortisol drawn at 2 PM will be physiologically lower than one drawn at 8 AM. Stress, recent illness, and exogenous corticosteroid use all distort results. The Endocrine Society's 2016 guideline on adrenal insufficiency recommends confirming any abnormal cortisol with a 250-µg cosyntropin stimulation test rather than acting on a single random sample 12.
DHEA-S
Dehydroepiandrosterone sulfate (DHEA-S) is the most abundant circulating steroid hormone. It declines steadily with age, roughly 2 to 3% per year after age 30. Low DHEA-S in a symptomatic patient may contribute to fatigue, low mood, or decreased bone density, although the clinical significance of supplementation remains debated. A 2019 Cochrane review found insufficient evidence to recommend routine DHEA supplementation for anti-aging purposes 13.
Insulin, HbA1c, and Metabolic Hormones
Metabolic hormone testing goes beyond glucose. Fasting insulin and hemoglobin A1c provide different information, and both belong on a thorough metabolic panel.
Fasting Insulin
Most labs list a fasting insulin reference range of 2.6 to 24.9 µIU/mL. A fasting insulin above 10 µIU/mL, even with a normal fasting glucose, may indicate early insulin resistance. Dr. Robert Lustig, professor of pediatric endocrinology at UCSF, has argued: "Insulin resistance precedes type 2 diabetes by a decade or more. If you wait for fasting glucose to rise, you have missed the window for prevention" 14.
HbA1c
Hemoglobin A1c reflects average blood glucose over the prior 2 to 3 months. The American Diabetes Association (ADA) diagnostic thresholds: normal <5.7%, prediabetes 5.7 to 6.4%, diabetes 6.5% or higher 15. An HbA1c of 5.5% with a fasting insulin of 18 µIU/mL tells a different story than an HbA1c of 5.5% with a fasting insulin of 4 µIU/mL. The first patient is compensating. The second is metabolically healthy.
HOMA-IR
The homeostatic model assessment of insulin resistance (HOMA-IR) combines fasting glucose and fasting insulin into a single score. The formula: (fasting insulin × fasting glucose) / 405, using conventional units. A HOMA-IR above 2.5 is generally considered indicative of insulin resistance 16.
How to Track Your Results Over Time
A single lab draw is a snapshot. Trends are more informative than isolated numbers.
Build a Tracking Habit
Record each result with the date, time of draw, lab name, and fasting status. Many patient portals export results as PDFs. A simple spreadsheet comparing values across draws reveals trajectories that a single report cannot.
Watch for Assay Changes
If your lab switches assay platforms (for example, from Roche to Abbott), reference ranges may shift. A TSH that appears to jump from 2.1 to 3.0 mIU/L may reflect the new assay rather than a true thyroid change. Always check whether the reference range printed on the report has changed.
When to Retest
The ATA recommends retesting thyroid function 6 to 8 weeks after any dose adjustment of levothyroxine 5. For testosterone, the Endocrine Society advises repeating a low result on a second morning before diagnosing hypogonadism 8. Retesting too soon after a medication change produces misleading data because most hormonal therapies require 4 to 8 weeks to reach steady state.
Red Flags That Require Immediate Attention
Most abnormal hormone results prompt a follow-up visit, not an emergency department trip. A few exceptions exist.
Thyroid Storm Indicators
A TSH below 0.01 mIU/L with a free T4 above 3.0 ng/dL in a patient with fever, tachycardia, and confusion is a medical emergency. Thyroid storm carries a mortality rate of 10 to 30% even with treatment 17.
Adrenal Crisis
A cortisol below 3 µg/dL with hypotension, nausea, and altered consciousness suggests adrenal crisis. This requires immediate intravenous hydrocortisone (100 mg bolus) and fluid resuscitation 12.
Severely Elevated Prolactin
A prolactin above 200 ng/mL strongly suggests a macroprolactinoma and warrants urgent MRI of the pituitary. Values between 25 and 200 ng/mL have a broader differential, including medication side effects (antipsychotics, metoclopramide) and stalk compression 18.
Bring your lab report to your appointment. Ask your clinician to explain any result that falls outside the reference range and any result that sits at the extreme end of it.
Frequently asked questions
›What is a normal TSH level?
›Can hormone lab results vary from day to day?
›What does it mean if my TSH is normal but I still feel tired?
›How often should I get my hormone levels checked?
›What is the difference between total and free testosterone?
›Should I fast before a hormone blood test?
›What does a high HOMA-IR score mean?
›Can medications affect hormone lab results?
›What is the best time of day to get blood drawn for hormones?
›Do reference ranges change with age?
›What is subclinical hypothyroidism?
›Why does my doctor order both free T4 and free T3?
References
- Horowitz GL. Defining, establishing, and verifying reference intervals in the clinical laboratory. CLSI document C28-A3c. Clin Lab Stand Inst. 2010. PubMed
- Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid. 2003;13(1):3-126. PubMed
- Taylor PN, Razvi S, Pearce SH, Dayan CM. A review of the clinical consequences of variation in thyroid function within the reference range. J Clin Endocrinol Metab. 2013;98(9):3562-3571. PubMed
- Bianco AC, Dumitrescu A, Gereben B, et al. Paradigms of dynamic control of thyroid hormone signaling. Endocr Rev. 2019;40(3):723-750. PubMed
- Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force. Thyroid. 2014;24(12):1670-1751. PubMed
- Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet. 2017;390(10101):1550-1562. PubMed
- Wiersinga WM, Duntas L, Fadeyev V, Nygaard B, Vanderpump MP. 2012 ETA guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidism. Eur Thyroid J. 2012;1(2):55-71. PubMed
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PubMed
- Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-2469. PubMed
- The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause. 2017;24(7):728-753. PubMed
- Practice Committee of the American Society for Reproductive Medicine. Diagnostic evaluation of the infertile female: a committee opinion. Fertil Steril. 2015;103(6):e44-e50. PubMed
- Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(2):364-389. PubMed
- Rutkowski K, Sowa P, Rutkowska-Talipska J, et al. Dehydroepiandrosterone (DHEA): hypes and hopes. Drugs. 2014;74(11):1195-1207. PubMed
- Lustig RH. Fat chance: beating the odds against sugar, processed food, obesity, and disease. J Pediatr Endocrinol Metab. 2012;25(7-8):e1-e2. PubMed
- American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: standards of care in diabetes, 2024. Diabetes Care. 2024;47(Suppl 1):S20-S42. ADA
- Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419. PubMed
- Akamizu T, Satoh T, Isozaki O, et al. Diagnostic criteria, clinical features, and incidence of thyroid storm. Thyroid. 2012;22(7):661-679. PubMed
- Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288. PubMed